Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Técnico, 1049-001, Lisbon, Portugal.
Appl Microbiol Biotechnol. 2013 Jun;97(12):5189-99. doi: 10.1007/s00253-013-4926-6. Epub 2013 May 4.
The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes of bioactive products to treat and prevent cancer growth and metastasis. In the first part of the article, we review the latest findings regarding the use of live bacteria and products as anti-cancer agents, paying special attention to immunotoxins, proteins, and peptides. In particular, we focus on the recent results of using azurin or its derived peptide as anticancer therapeutic agents. In the second part, we discuss the challenges of using metagenomic techniques as a distinctive approach for discovering new anti-cancer agents from bacterial origin.
利用活细菌进行癌症治疗提供了令人兴奋的可能性。如今，越来越多的经过基因工程改造的细菌出现在这一领域，它们在治疗和诊断方面都有应用。与此同时，作为治疗和预防癌症生长和转移的新型生物活性产品，纯化的细菌产物也越来越受到关注。在文章的第一部分，我们回顾了利用活细菌和细菌产物作为抗癌药物的最新发现，特别关注免疫毒素、蛋白质和肽。具体来说，我们重点介绍了使用天青蛋白或其衍生肽作为抗癌治疗剂的最新结果。在第二部分，我们讨论了使用宏基因组技术作为一种独特方法来发现源自细菌的新型抗癌药物所面临的挑战。
